60
Participants
Start Date
September 30, 2006
Primary Completion Date
February 28, 2009
Study Completion Date
June 30, 2010
Rate Control
Metoprolol 50-100mg
Ablation Therapy
Rate Control
Atenolol 50-100mg,
Rate control
Propranolol 40-80mg
Rate control
Acebutolol 200mg
Rate control
Carvedilol 6.25mg
Rate Control
Diltiazem 180-240mg
Rate Control
Verapamil 180-240mg
Rate Control
Digoxin 0.125mg
Rhythm Control
Propafenone 450mg
Rhythm control
Flecainide 200mg
Rhythm control
Sotalol 240mg
Rhythm control
Dofetilide 500mcg
Rhythm control
Amiodarone 200mg
Rhythm control
Quinidine 600-900mg
University of Pennsylvania Health, Philadelphia
Johns Hopkins Hospital, Baltimore
Universtity of Alabama Hospital, Birminham
Ohio State University Medical Center, Columbus
Mercy Medical Center, Des Moines
Mayo Clinic, Rochester
Loyola University, Maywood
Intermountain Medical Center, Murray
Good Samaritan Hospital, Los Angeles
Brigham and Womens Hospital, Boston
Lead Sponsor
Collaborators (2)
Duke Clinical Research Institute
OTHER
Abbott Medical Devices
INDUSTRY
Mayo Clinic
OTHER